So excited to host
@MartinBJensen on this week's episode the Free Radicals podcast!
As the co-founder and CSO of
@GordianBio, Martin has raised over $60M from top investors like
@foundersfund ,
@HorizonsHK ,
@fiftyyears and The Longevity Fund, to revolutionize testing of therapeutics and targets at scale. Gordian also recently announced a partnership with
@pfizer!
Martin is also a prominent voice in longevity, and as the founder of
@NornGroup he has also made countless contributions to the field more broadly, including through
@impetusgrants.
In this episode, Martin shares his insightful thoughts on the longevity field broadly, and also deep dives into Gordian's technology. This was a fun, wide ranging episode.
Be sure to follow me and
@EricDai_BioE to stay up to date on the latest news in longevity biotech! And special thank you to
@NFX &
@omri_drory for lending us their beautiful podcasting studio!
0:00 Intro
03:27 Where is the longevity field today and are we on track to cure aging in our lifetimes?
14:25 Is longevity truly different from other areas of biotechnology?
16:07 What is aging?
22:13 An aging body is like a company that’s developed toxic bureacracy
26:46 Gordian’s approach to tackling aging
45:09 Will scale alone solve biology?
49:08 What data would superintelligent AI need to cure aging?
54:00 Unified theory of aging or biology
59:26 What understudied areas in aging deserve more attention?
1:02:23 How does loss of cellular identity relate to aging and disease?
1:10:07 Why are there no trillion-dollar biotechs and what would it take to create one?
1:17:32 What are the key components needed for a biotech flywheel?
1:21:43 How can biotech companies de-risk clinical development?
1:37:02 What is Norn Group and what problems does it address?
1:43:58 What opportunities exist for individuals to impact the aging field?